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Abstract
Covalent phosphorylation of glycogen, first described 35 years ago, was put on firm ground 
through the work of the Whelan laboratory in the 1990s. But glycogen phosphorylation lay fallow 
until interest was rekindled in the mid 2000s by the finding that it could be removed by a 
glycogen-binding phosphatase, laforin, and that mutations in laforin cause a fatal teenage-onset 
epilepsy, called Lafora disease. Glycogen phosphorylation is due to phosphomonoesters at C2, C3 
and C6 of glucose residues. Phosphate is rare, ranging from 1:500 - 1:5000 phosphates/glucose 
depending on the glycogen source. The mechanisms of glycogen phosphorylation remain under 
investigation but one hypothesis to explain C2 and perhaps C3 phosphate is that it results from a 
rare side reaction of the normal synthetic enzyme glycogen synthase. Lafora disease is likely 
caused by over-accumulation of abnormal glycogen in insoluble deposits termed Lafora bodies in 
neurons. The abnormality in the glycogen correlates with elevated phosphorylation (at C2, C3 and 
C6), reduced branching, insolubility and an enhanced tendency to aggregate and become 
insoluble. Hyperphosphorylation of glycogen is emerging as an important feature of this deadly 
childhood disease
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1. Introduction
Bill Whelan’s career has spanned many decades and many research interests, though the 
latter were unified by his passion for carbohydrates, and storage polymers like glycogen and 
starch in particular. My own work since the 1980s has sometimes overlapped with Bill’s, 
especially in the area of glycogenin, whose discovery ranks among Bill’s most notable 
achievements and which is addressed in other articles of this issue. Here, though, I will 
focus on another, seemingly esoteric feature of glycogen metabolism on which Bill had 
made important observations in the early 1990s, namely the covalent phosphorylation of 
glycogen. His work lay relatively undisturbed in the literature until quite recently when it 
began to be appreciated that excessive phosphorylation of glycogen was associated with, and 
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might even cause, Lafora disease, a rare but deadly teenage-onset form of epilepsy. And so 
our work once again bumped into key findings made by the Whelan laboratory.
2. Glycogen phosphorylation
2.1. History
Phosphate is a relatively abundant and ubiquitous biomolecule and, as such, is a potential 
and frequent contaminant of many purified cellular constituents. Such was true for purified 
glycogen and, indeed, in early studies, low phosphate content was viewed as a positive 
indicator of the purity of the glycogen (Mordoh et al., 1966; Northcote, 1954; Wanson and 
Drochmans, 1968). Already, however, plant starch, which resembles glycogen in being a 
branched polymer of glucose, was recognized as containing covalent phosphate (Hizukuri et 
al., 1970). The first convincing report of stably bound phosphate in glycogen was by 
Fontana (Fontana, 1980) in 1980. Whelan and colleagues followed up with a series of 
studies (Kirkman and Whelan, 1990; Lomako et al., 1994; Lomako et al., 1993) in which 
they confirmed the presence of covalent phosphate, suggested that it was present as a C6 
phosphomonester or as a C1-C6 phosphodiester, and proposed the existence of an enzyme, 
separate from glycogen synthase, that could transfer a glucose-phosphate moiety from UDP-
glucose to form the phosphodiester linkage.
2.2. Chemistry
The chemistry of the attachment of phosphate to glycogen was re-visited recently, in large 
part because of the discovery of a mechanism to release it from glycogen by a phosphatase 
called laforin (Tagliabracci et al., 2007). Laforin is the product of the EPM2A gene, one of 
two genes whose mutation causes Lafora disease (Chan et al., 2003; Minassian et al., 1998; 
Serratosa et al., 1999). In Epm2a−/− mice (hereafter designated laforin−/− mice), a rodent 
model of the human disease, the phosphorylation of glycogen increases up to ten-fold as the 
animals age (Tagliabracci et al., 2007) and the excess phosphate appears to contribute 
significantly to the pathology of the disease (see section 2.5). The stoichiometry of glycogen 
phosphorylation is low, in the range of 1 phosphate per 500 glucoses to 1 phosphate per 
several thousand glucoses, depending on the source of glycogen and the particular study. 
Because of the scarcity of the phosphate, we hydrolyzed rabbit muscle glycogen with 
glucosidases and enriched for negatively charged species by anion exchange 
chromatography (Tagliabracci et al., 2011). Analysis of the bound material by mass 
spectrometry indicated a mixture of compounds dominated by species with masses 
corresponding to hexose oligosaccharides plus a phosphate, consistent with the purification 
of phospho-oligosaccharides of glucose. Despite the size-heterogeneity, analysis of this 
sample by NMR gave clear signals indicative of glucose phospho-monoesters at the C2 and 
the C3 atoms but did not observe either C6 phosphate or phosphodiesters. A subsequent 
study (Nitschke et al., 2013), using similar methods for purification of phospho-
oligosaccharides, detected C2, C3 as well as C6 phosphate by NMR, but, as in our work, did 
not observe phospho-diesters (Tagliabracci et al., 2011). In addition, Nitschke et al. 
(Nitschke et al., 2013) measured glucose-6-P directly in hydrolysates of glycogen from 
mouse and rabbit sources. The two papers presented conflicting views as to the presence of 
C6 phosphate in glycogen; we therefore pursued the question further, testing the hypothesis 
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that methods of purifying glycogen might affect the phosphorylation pattern (DePaoli-Roach 
et al., 2015). We analyzed rabbit muscle glycogen isolated by our previous, relatively gentle 
procedure, in fact following more or less the old Whelan protocol used to preserve 
glycogenin attached to the glycogen (Kennedy et al., 1985). In addition, we used a more 
extreme procedure in which powdered frozen muscle is treated first with boiling KOH. 
Results from either protocol were similar and in both cases we now detected C6 
phosphorylation by NMR analyses (DePaoli-Roach et al., 2015). We also developed a 
sensitive assay for glucose-6-P in glycogen hydrolysates and were able to quantitate C6 
phosphorylation in glycogen samples that, combined with analysis of total covalent 
phosphate, permitted us to calculate the relative contribution of C6 and C2 + C3 
phosphorylation to the total phosphate content. C6 phosphate typically making up around 
20% of the total phosphate with C2 + C3 phosphate accounting for the majority, around 
80%, in either mouse or rabbit muscle glycogen samples (DePaoli-Roach et al., 2015). This 
phosphate distribution contrasts with amylopectin in which most phosphate is associated 
with C6 (Blennow et al., 2002; Stitt and Zeeman, 2012), for example ~90% in our recent 
study of potato amylopectin, the rest of the phosphate at C3, and little evidence for 
significant phosphorylation at C2 (DePaoli-Roach et al., 2015). Though the presence of 
phosphodiesters cannot be completely discounted, these recent studies did not find any 
indications for their existence.
2.3 Metabolism
The metabolism of the covalent phosphate within glycogen is not yet fully understood. The 
laforin phosphatase (Minassian et al., 1998; Serratosa et al., 1999) by sequence belongs to 
the atypical dual specificity protein phosphatase (DSP) sub-family (Alonso et al., 2004). 
Laforin is unique in being the only protein phosphatase in the genome that contains a built-
in carbohydrate binding domain (CBM20) at its N-terminus as well as a phosphatase 
domain. After an essentially fruitless search for protein substrates, it emerged that laforin 
can act on polysaccharide substrates like amylopectin (Tagliabracci et al., 2007; Worby et 
al., 2006) and glycogen (Tagliabracci et al., 2007). In biochemical experiments, mutation of 
the CBM to disable carbohydrate binding also eliminates the ability of laforin to 
dephosphorylate glycogen while leaving the active site capable of hydrolyzing generic 
substrates like p-nitrophenol phosphate (Tagliabracci et al., 2007). Glycogen purified from 
the muscle of mice lacking laforin contains elevated levels of phosphate compared with 
controls (Tagliabracci et al., 2008; Tagliabracci et al., 2007). Therefore, it is currently quite 
well accepted that laforin functions as a glycogen phosphatase in vivo. Plants contain two 
glycan phosphatases, SEX4 and LSF2, that remove the phosphate esters present in 
amylopectin (Fettke et al., 2009; Stitt and Zeeman, 2012; Zeeman et al., 2010). These 
enzymes resemble laforin in that they also contain CBMs although the architecture is 
different, the CBMs being C-terminal. In addition, the plant phosphatases are thought to act 
physiologically on smaller glucans generated from the breakdown of amylopectin (Fettke et 
al., 2009; Stitt and Zeeman, 2012; Zeeman et al., 2010). Although laforin can 
dephosphorylate phospho-oligosaccharides larger than three glucoses in length, it most 
likely acts on large glycogen molecules in vivo.
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Glycogen is also degraded in lysozomes and, though the relative contribution of this process 
compared with the classic cytosolic pathway (phosphorylase/debranching enzyme) is not 
well defined, its importance is underscored by the severity of Pompe disease, in which the 
lysosomal α-glucosidase is defective (Hirschhorn and Reuser, 2000; Raben et al., 2002; 
Reuser et al., 1995). Presumably the battery of hydrolytic activities within the lysosome 
would normally have no difficulty removing any phosphate attached to glucose or 
oligosaccharides derived from glycogen. The specifics of the trafficking of glycogen to the 
lysozome are poorly understood though it is likely to have similarities to autophagic 
pathways and to involve vesicular engulfment of glycogen particles. In a mouse model of 
Pompe disease, glycogen-laden autophagosomes are seen to accumulate in muscle (Fukuda 
et al., 2006). We have proposed that the glycogen binding protein Stbd1 might play a role in 
mediating the vesicular transport of glycogen to lysosomes (Jiang et al., 2010). Furthermore, 
since Stbd1 binds more tightly to the hyperphosphorylated glycogen purified from laforin−/
− mice, one could even imagine the selective disposal of excessively phosphorylated and 
abnormal glycogen. This idea interestingly aligns with suggestions of Bill Whelan’s from 
over twenty years ago (Lomako et al., 1994) that glycogen phosphate might have something 
to do with lysosomal targeting and that phosphorylation of glycogen molecules increases 
with their age. However, the idea that glycogen phosphorylation is related to lysosomal 
targeting remains a hypothesis at this time.
The mechanism by which phosphate is introduced into glycogen remains unresolved (Table 
1). From the polysaccharide literature, there were two main possibilities. The first was the 
glucose-1-phosphotransferase proposed by Lomako et al. (Lomako et al., 1993) which 
would bring phosphate in a C1-C6 phosphodiester linkage to form a novel type of branch 
point in glycogen. The second would be a glycogen water dikinase by analogy to the 
enzymes that are responsible for the phosphorylation of amylopectin. Glucan water dikinase 
(GWD) introduces phosphate at C6 (Mikkelsen et al., 2004) and a second enzyme, 
phosphoglucan water dikinase (PWD), phosphorylates C3 but preferentially in substrates 
that have been previously phosphorylated at C6 (Baunsgaard et al., 2005; Kotting et al., 
2005). However, neither bioinformatic nor biochemical investigations have yielded evidence 
for comparable enzymes in mammals. A priori, one could also postulate the existence of 
glycogen kinases that would transfer the γ-phosphate of ATP, or other nucleoside 
triphosphates, to a glucose residue within glycogen. Alternatively, other high energy 
compounds, such as phosho-enol-pyruvate or creatine phosphate, could serve as phosphate 
donors. Once introduced, phosphomonoesters in glucose residues might be re-distributed 
among glucose carbons in reactions somewhat akin to the phosphoglucomutase of 
intermediary metabolism. If such an enzyme existed, we might need only one primary 
mechanism for the introduction of phosphate into the polysaccharide. Phosphate migration is 
a well-established phenomenon in the chemistry of sugar esters (MacDonald, 1972; Patel 
and Davis, 2013; Teranishi and Ueno, 2003). There is however no indication, at the time of 
writing, for any of the preceding mechanisms for glycogen phosphorylation.
Our own efforts to address the matter began with the proposed glucose-1-
phosphotransferase. After synthesizing the needed [β-32P]UDP-glucose substrate, we 
showed that a mouse muscle extract could indeed transfer 32P to glycogen (Tagliabracci et 
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al., 2011), consistent with the hypothesis of Lomako et al. (Lomako et al., 1993). However, 
an extract from mouse muscle genetically lacking glycogen synthase was negative, 
suggesting that the phosphotransferase might be glycogen synthase itself. A series of in vitro 
experiments using highly purified glycogen synthase from rabbit muscle or purified 
recombinant glycogen synthase from yeast or from human confirmed that the enzyme 
mediated the introduction of phosphate when incubated with glycogen and UDP-glucose. 
We suggested that this was a rare side reaction happening at a rate of about one in 10,000 
normal catalytic cycles. The 32P was reduced to background when the product was 
incubated either with glucosidase enzymes, to degrade the glycogen, or laforin, to hydrolyze 
phosphomonesters. How, then, might glycogen synthase catalyze the introduction of 
phosphate? One possibility was suggested by the early work of Leloir on nucleoside 
diphosphate sugars, notably UDP-glucose. His laboratory described its tendency, under 
certain conditions such as the presence of divalent metal cations, to form what he called 
“fast ester” because on TLC it ran ahead of UDP-glucose (Paladini and Leloir, 1952). Fast 
ester is, in fact, glucose-1,2-cyclic phosphate and we speculated that, if this diester could 
form in the catalytic site of glycogen synthase, it might be transferred by essentially the 
normal catalytic mechanism to a growing glycogen chain to add a glucose with phosphate at 
the C2 position (Tagliabracci et al., 2011). One could even envision a glucose-1,3-cyclic 
phosphate intermediate resulting in phosphate at C3. To prove such hypotheses is especially 
challenging but enzymological and structural studies did provide further support (Chikwana 
et al., 2013). First, a crystal structure of glycogen synthase with glucose-1,2-cyclic 
phosphate bound showed that the catalytic site could accommodate the cyclic ester in a 
manner consistent with the proposed mechanism. Secondly, incubation of glycogen synthase 
with UDP-glucose resulted in the generation of the cyclic phosphate.
This proposed mechanism for glycogen phosphorylation has been challenged by Nitschke et 
al. (Nitschke et al., 2013) who suggested that the 32P-incorporation into glycogen that we 
described (Tagliabracci et al., 2011) was not covalently attached phosphate but the result of 
tight binding to glycogen of the [β-32P]UDP formed from [β-32P]UDP-glucose by the 
normal glycogen synthase reaction. Our protocol for monitoring glycogen phosphorylation 
utilizes SDS-PAGE in which glycogen is mostly retained at the top of and within the 
stacking gel. Such binding to glycogen by UDP would need to be strong enough to survive 
the initial ethanol precipitation of glycogen, boiling in SDS gel electrophoresis buffer and 
the process of electrophoresis itself. Nitschke et al. (Nitschke et al., 2013) reported that 
the 32P-glycogen signal generated by such reactions was reduced to a low level by gel 
filtration with Sephadex G50 prior to SDS-PAGE, supporting their conclusion that the 32P 
was not covalently linked to glycogen. We have revisited our experiments and conducted 
several additional controls (Contreras, DePaoli-Roach and Roach, unpublished results). In 
our hands, gel filtration did not eliminate the 32P signal from glycogen analyzed by SDS-
PAGE nor did addition of large molar excesses of unlabeled UDP. In addition, we 
confirmed that the 32P-labeling was removed from glycogen by laforin and furthermore 
showed that laforin was unable to hydrolyze the β-phosphate of UDP. Based on these, and 
other, results, we stand by our original conclusions regarding the phosphorylation of 
glycogen by glycogen synthase (Tagliabracci et al., 2011). It is very difficult to be certain of 
the explanations in instances of discordant results like this. We do indeed find that, at the 
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very high specific radioactivities needed for the experiments, 32P contamination of glycogen 
is an issue that needs to be carefully addressed. Our data, though, convince us that the 32P-
signal that we monitor is neither non-specific radioactivity nor [β-32P]UDP.
A glucose cyclic phosphate mechanism, such as described above, may account for the 
presence of C2 phosphate in glycogen, and perhaps even C3 phosphate since both 
glucose-1,2-cyclic phosphate and glucose-1,3-cyclic phosphate are known (Zmudzka and 
Shugar, 1964). Although C6 cyclic phosphates involving C3 or C4 have been described 
(Zmudzka and Shugar, 1964), a glucose-1,6-cyclic phosphate is sterically impossible, 
precluding its direct generation from UDP-glucose. It is hard to imagine how the β-
phosphate of UDP-glucose, linked to C1 of the glucose, could end up at C6 unless via an 
intermediate glucose-3,6-cyclic phosphate, a rather complex mechanism. Therefore, the 
origin of the C6 phosphate remains a mystery and perhaps further exploration of some of the 
possibilities listed in Table 1, or another not thought of, will one day solve the puzzle.
2.4 Function
Normal glycogen contains a low, basal level of phosphorylation. As with any biological 
phenomenon, the first instinct is to seek a biological function for glycogen phosphate that 
can provide the evolutionary rationale for its existence. Is there a function for the trace 
amounts of covalent phosphate in glycogen? The question seems all the more relevant since 
there is a substantial experimental basis to suggest that phosphorylation of amylopectin, a 
biological cousin of glycogen, serves a definite purpose in the degradation of the polymer 
(Blennow et al., 2002; Fettke et al., 2009; Stitt and Zeeman, 2012; Zeeman et al., 2010). 
However, despite the considerable similarities in the overall metabolism and function of 
starch and glycogen, there are many key differences that make such comparative arguments 
less compelling. Unlike glycogen, starch contains highly structured, insoluble semi-
crystalline segments not accessible to normal enzymatic attack (Blennow and Engelsen, 
2010; Fettke et al., 2009; Perez and Bertoft, 2010). The role of phosphorylation in starch 
breakdown appears to be the disruption of that semi-crystalline structure, allowing exposure 
to water so that hydrolytic enzymes can access and cleave the polymer. A similar role in 
glycogen degradation seems unlikely. In fact, hyperphosphorylation of glycogen promotes 
insolubility in water (Tagliabracci et al., 2008). Could phosphorylation serve other evolved 
functions in glycogen? One suggestion has been that C6 phosphorylation is involved in 
determining α-1,6-branches and thus might control the branching pattern of glycogen 
(Nitschke et al., 2013). Certainly a C6 phosphomonoester would block the ability to form an 
α-1,6-glycosidic linkage but the frequency of C6 phosphorylation is very low so that less 
than 1% of potential branch points are affected (DePaoli-Roach et al., 2015). Even under 
conditions of pathologically elevated glycogen phosphorylation as in Lafora disease 
(Section 2.5), the frequency of C6 phosphorylation is increased no more than about 10-fold. 
There is clearly some relationship between excessive phosphorylation of glycogen and 
branching but any impact of phosphorylation on branching pattern is likely by a more 
indirect mechanism. Discovery of some glycogen phosphorylating activity (Table 1), one 
that requires additional enzyme(s) and/or protein(s), would provide powerful evidence that 
phosphorylation of glycogen serves an as yet undetermined purpose since maintenance of 
the associated genes would have had to withstand the selective pressures of evolution.
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An alternative is that glycogen phosphorylation has no evolved function and is the result of a 
side reaction (Roach, 2011). For C2 and perhaps C3 phosphorylation, that side reaction 
could be mediated by glycogen synthase (Tagliabracci et al., 2011). Although many 
metabolic enzymes have apparently singular functions in cells, it is also clear that some 
enzymes can catalyze more than one chemical reaction, whether by design or by accident. In 
the interconversion of soluble small molecules, generation of trace amounts of 
physiologically irrelevant species by a side reaction or catalytic error may seldom have an 
impact. Such species may be excreted or metabolized by existing pathways. In the case of 
macromolecules, however, the situation is fundamentally different since most have 
significant lifetimes, some very long. The extreme is probably DNA which is synthesized 
once per cell division. And indeed, the severe consequence of errors in DNA synthesis has 
led to the evolution of complex mechanisms to ensure the fidelity of replication and to repair 
damage incurred post-synthesis (Kunkel and Bebenek, 2000). Similarly, sophisticated 
evolved mechanisms ensure the fidelity of RNA (Thomas et al., 1998) and protein synthesis 
(Zaher and Green, 2009). In glycogen, phosphate introduced by side reactions, or indeed by 
any mechanism, must remain attached to the polysaccharide through cycles of synthesis and 
degradation since there is normally a basal level of phosphorylation. However, excessive 
glycogen phosphorylation, such as when laforin is defective, has dire consequences and is to 
be avoided (Section 2.5). Laforin acts to oppose phosphate accumulation and thus might be 
viewed as part of a “repair” or “damage control” mechanism.
2.5 Lafora disease
Lafora disease (Andrade et al., 2007; Delgado-Escueta, 2007; Ganesh et al., 2006; Gentry et 
al., 2009; Roach and DePaoli-Roach, 2013) is a teenage-onset progressive myoclonic 
epilepsy that is inevitably fatal, usually within a decade of the appearance of symptoms. 
Approximately 90% of cases are caused by mutations in either of two genes, EPM2A and 
EPM2B (also called NHLRC1)(Ganesh et al., 2006; Ramachandran et al., 2009). As noted, 
EPM2A encodes laforin (Minassian et al., 1998; Serratosa et al., 1999) and the EPM2B gene 
encodes malin which contains an N-terminal RING finger domain followed by six NHL 
domains (Chan et al., 2003). The RING finger domain is characteristic of E3 ubiquitin 
ligases (Freemont, 2000), an activity that has been demonstrated biochemically (Gentry et 
al., 2005). A characteristic of Lafora disease is the accumulation, in neurons, muscle, heart, 
skin and several other tissues, of Lafora bodies, insoluble deposits that contain 
polyglucosan, a poorly branched, glycogen-like polymer (Carpenter and Karpati, 1981; 
Collins et al., 1968; DiMauro and Lamperti, 2001).
Since the identification of the laforin and malin genes, much effort has been directed at 
understanding the functions of the corresponding proteins. Most would agree that laforin can 
act as a physiological glycogen phosphatase (Tagliabracci et al., 2007). The function of 
malin is less clear. Based primarily on experiments with cultured cells, several malin 
substrates have been proposed (Cheng et al., 2007; Gentry et al., 2005; Moreno et al., 2010; 
Sharma et al., 2011; Solaz-Fuster et al., 2008; Vilchez et al., 2007; Worby et al., 2008) but 
results with Epm2b−/− mice (malin−/− mice) do not provide simple confirmation of these as 
malin targets (DePaoli-Roach et al., 2010). Nonetheless, in both patients and mice, defects 
in laforin and malin lead to generally similar phenotypes, both neurologically and 
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biochemically (Andrade et al., 2007; Delgado-Escueta, 2007; Ganesh et al., 2006; Garcia-
Cabrero et al., 2012; Gentry et al., 2009; Roach and DePaoli-Roach, 2013). Both laforin−/− 
and malin−/− mice have elevated levels of glycogen and glycogen total phosphorylation 
(DePaoli-Roach et al., 2015; Tagliabracci et al., 2007; Turnbull et al., 2010). The fold 
increases in C6 and in C2 + C3 phosphate, in either laforin−/− or malin−/− mice, were 
similar so that, as of now, it is impossible to conclude that phosphorylation at any particular 
site in glucose is more important.
How does covalent phosphorylation of glycogen affect structure? Because the structure of 
glycogen is not amenable to determination by classic methods such as X-ray 
crystallography, it is difficult to probe directly the effect of the phosphate. However, the 
crystal structure of a cycloamylose, a 26-residue cyclic polymer of glucose in α-1,4-
linkages, has been determined (Gessler et al., 1999). The structure is composed of two 
antiparallel polyglucose helices with the glucose oxygens oriented toward the exterior 
surface and the carbon skeletons of the glucoses lining the interior of the helix. Although the 
helices are constrained by the cyclic nature of the oligosaccharide, it is likely that many 
features of the helices reflect those present in glycogen. In the cycloamylose structure, the 
helices are stabilized by intrahelical hydrogen bonding mediated by the physically adjacent 
C6, C2 and C3 hydroxyls. Therefore, introduction of phosphate groups to any of these 
glucose hydroxyl groups would disrupt the hydrogen bonding and potentially destabilize the 
structure. For amylopectin, it has been suggested that C3 phosphorylation induces strain in 
the helix; though C6 phosphate is more tolerated, it would also affect the packing of helices 
(Blennow and Engelsen, 2010).
These ideas are consistent with the notion that a relatively small number of phosphates in 
glycogen have far reaching effects on structure and on the physical chemical properties of 
the polymer. This is quite evident from the analysis of glycogen from laforin−/− mice 
(Tagliabracci et al., 2008). Muscle glycogen purified from these animals is more soluble in 
ethanol, to such a degree that we could genotype mice based solely on this property. The 
glycogen is less soluble in water and less branched. By electron microscopy, the glycogen 
from the laforin−/− mice forms large aggregates of individual glycogen particles that have a 
distinct appearance compared with wild type glycogen. Exposure to laforin returned the 
morphology of the laforin−/− glycogen closer to that of wild-type glycogen. Nonetheless, 
these major differences in the properties of glycogen were associated with only a ~10-fold 
increase in phosphorylation in the laforin−/− mice, from 1:1500 to 1:150 phosphates per 
glucose. The changes in glycogen properties in the absence of laforin, decreased water 
solubility and increased propensity to aggregate, would seem conducive to the formation of 
Lafora bodies. It should be emphasized that an important characteristic of the abnormal 
glycogen associated with Lafora bodies, besides elevated phosphate, is the reduced 
branching. The interplay between phosphorylation and branching structure in the generation 
of the abnormal glycogen of Lafora bodies remains an unresolved and critical issue in 
understanding the molecular basis of the disease.
Because of the abnormal metabolism of glycogen in the mouse models, one can ask whether 
Lafora disease should be classified as a glycogenosis. Several studies of genetically 
modified mice have indeed demonstrated that Lafora bodies are causative of the disease. 
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Both laforin−/− and malin−/− mice accumulate Lafora bodies and develop neurological 
abnormalities (Criado et al., 2012; DePaoli-Roach et al., 2015; DePaoli-Roach et al., 2010; 
Ganesh et al., 2002; Garcia-Cabrero et al., 2012; Tagliabracci et al., 2007; Turnbull et al., 
2010; Valles-Ortega et al., 2011). PTG is a type 1 protein phosphatase targeting subunit that 
binds glycogen and activates glycogen synthase; PTG−/− mice have decreased glycogen 
accumulation in muscle and brain (Zhai et al., 2007). Disruption of the mouse PTG gene in 
either a laforin−/− (Turnbull et al., 2011) or malin−/− ((Turnbull et al., 2014); DePaoli-
Roach, Segvich, Contreras and Roach, unpublished) genetic background decreases glycogen 
accumulation, suppresses Lafora body formation and alleviates neurological symptoms. In 
addition, complete or even partial elimination of brain glycogen by disruption of the Gys1 
gene in laforin−/− or malin−/− mice abolished Lafora body formation and restored 
neurological functions (Duran et al., 2014; Pederson et al., 2013). Thus, evidence is 
accumulating that Lafora disease is a glycogen storage disease and a promising therapeutic 
approach may be to suppress glycogen synthesis in the brain. Mice totally lacking brain 
glycogen, surprisingly, do not display any obvious neurological defects.
3. Conclusion
It is, I think, fair to say that we are quite far from understanding the phosphorylation of 
glycogen and its role in health and disease. However, it is fascinating to see how the field 
has progressed from the early report of Fontana (Fontana, 1980), through Bill Whelan’s 
studies in the 1990s, to the recent work that was spurred on by the potential connection of 
glycogen phosphorylation with Lafora disease, a deadly neurological disorder. Bill Whelan, 
throughout his career, has had an uncanny ability to latch on to significant, sometimes 
seemingly simple, observations that end up being of considerable importance.
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Table 1
Some possible mechanisms to mediate glycogen phosphorylation
Shown are some potential enzymic reactions that could introduce phosphate into glycogen or re-arrange its 
location. X~P, unspecified high energy phosphate donor.
Enzyme Reaction Group
transferred
Glucose-1-
phosphotransferase
UDP-glucose + glycogenn → UMP +
glycogenn+1-P
glucose-1-
phosphate
Glycogen synthase UDP-glucose + glycogenn → UMP +
glycogenn+1-P
glucose-1-
phosphate
Glycogen dikinase ATP + H2O + glycogen → AMP + Pi +
glycogen-P
Pi
Glycogen kinase NTP + glycogen → NDP + glycogen-P Pi
Other
phosphotransferase
X~P + glycogen → X + glycogen-P Pi
Mutase glycogen-P(site 1) → glycogen-P(site 2) Pi
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